Nasus Pharma Ltd NSRX
Biotechnology: Pharmaceutical Preparations · IPO 2025 · data as of November 13, 2026
Nasus Pharma Ltd (NSRX) is a healthcare company listed in the US with a market value of about $34M. In fiscal year 2025 it had revenue of $1.2B and net income of -$6M, a net margin of -0.5%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is future growth (0/5).
Key numbers: a 5-year average ROIC of -134%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 1655% above the current price.
About Nasus Pharma
Nasus Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2025. It was profitable in 0 of the last 3 years in our data. It spends 0% of revenue on research and development.
Score: 0.8 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $1.2B | — | — |
| Net income | -$6M | -$2M | -$1M |
| Free cash flow | -$5M | — | — |
| EPS (diluted) | $-0.50 | $-0.13 | $-0.09 |
| Net margin | -0.5% | — | — |
| ROIC | -134.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Nasus Pharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 1655% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Nasus Pharma pay a dividend?
Not currently.
Is Nasus Pharma a good stock to buy?
We do not give buy or sell advice. Nasus Pharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.